ATE309802T1 - Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen - Google Patents
Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungenInfo
- Publication number
- ATE309802T1 ATE309802T1 AT03723620T AT03723620T ATE309802T1 AT E309802 T1 ATE309802 T1 AT E309802T1 AT 03723620 T AT03723620 T AT 03723620T AT 03723620 T AT03723620 T AT 03723620T AT E309802 T1 ATE309802 T1 AT E309802T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclopamine
- corticosteroid
- skin
- lesions
- treatment
- Prior art date
Links
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 title abstract 5
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 title abstract 5
- 201000004681 Psoriasis Diseases 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 abstract 3
- 230000003902 lesion Effects 0.000 abstract 2
- 230000001185 psoriatic effect Effects 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000008034 disappearance Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002615 epidermis Anatomy 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002203 pretreatment Methods 0.000 abstract 1
- 231100000444 skin lesion Toxicity 0.000 abstract 1
- 206010040882 skin lesion Diseases 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2002/000017 WO2002078704A1 (en) | 2001-07-02 | 2002-04-19 | Use of cyclopamine in the treatment of psoriasis |
| PCT/TR2003/000017 WO2003088964A1 (en) | 2002-04-19 | 2003-03-17 | Use of cyclopamine in the treatment of psoriasis and other skin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE309802T1 true ATE309802T1 (de) | 2005-12-15 |
Family
ID=29247069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03723620T ATE309802T1 (de) | 2002-04-19 | 2003-03-17 | Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7893078B2 (de) |
| EP (2) | EP1411938B1 (de) |
| JP (1) | JP2006512281A (de) |
| KR (4) | KR20080096605A (de) |
| CN (2) | CN1835748A (de) |
| AT (1) | ATE309802T1 (de) |
| AU (1) | AU2003230541B2 (de) |
| BR (1) | BR0309396A (de) |
| CA (3) | CA2452152A1 (de) |
| DE (1) | DE60302348T2 (de) |
| DK (1) | DK1496895T3 (de) |
| EA (1) | EA200401355A1 (de) |
| ES (1) | ES2253672T3 (de) |
| MX (1) | MXPA04010294A (de) |
| WO (1) | WO2003088964A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| CA2386190C (en) | 1999-10-13 | 2009-04-14 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US20170326118A1 (en) * | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| EP2862570A1 (de) * | 2001-07-02 | 2015-04-22 | Sinan Tas | Verwendung von Cyclopamin bei der Behandlung eines Basalzellkarzinoms und anderen Tumoren |
| EP1411938B1 (de) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis |
| ES2578728T3 (es) | 2004-08-27 | 2016-07-29 | Infinity Pharmaceuticals, Inc. | Proceso para la preparación de compuestos análogos de ciclopamina |
| JP2008514726A (ja) * | 2004-09-30 | 2008-05-08 | ザ ユニヴァーシティー オヴ シカゴ | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP2511298B1 (de) | 2005-10-31 | 2019-01-16 | Oncomed Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Behandlung von Krebs unter Verwendung von menschlichen FZD Rezeptoren |
| US20090156611A1 (en) * | 2005-11-11 | 2009-06-18 | Licentia Ltd. | Mammalian hedgehog signaling modulators |
| EP1998785A4 (de) * | 2006-02-21 | 2009-06-17 | Univ Michigan | Krebsbehandlung mithilfe eines hedgehog-signalisierungspfades |
| US20110034498A1 (en) * | 2006-03-24 | 2011-02-10 | Mcgovern Karen J | Dosing regimens for the treatment of cancer |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| WO2008109184A1 (en) * | 2007-03-07 | 2008-09-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
| JP2010520310A (ja) | 2007-03-07 | 2010-06-10 | インフィニティ・ディスカバリー・インコーポレイテッド | シクロパミンラクタム類似体及びその使用方法 |
| US20090181997A1 (en) * | 2007-12-27 | 2009-07-16 | Grayzel David | Therapeutic cancer treatments |
| US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
| CN104059124A (zh) | 2007-12-27 | 2014-09-24 | 无限药品股份有限公司 | 立体选择性还原的方法 |
| CN101990542A (zh) * | 2008-02-08 | 2011-03-23 | 德克萨斯大学董事会 | 环巴胺酒石酸盐及其用途 |
| GB0813740D0 (en) * | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| GB0900484D0 (en) | 2009-01-13 | 2009-02-11 | Angeletti P Ist Richerche Bio | Therapeutic agent |
| JP6141015B2 (ja) | 2009-08-05 | 2017-06-07 | インフィニティ ファーマスーティカルズ、インク． | シクロパミン類似体の酵素によるアミノ基転移 |
| GB0916608D0 (en) | 2009-09-22 | 2009-11-04 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2501237A1 (de) * | 2009-11-06 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Orale formulierungen eines hedgehog-pfad-hemmers |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| US20110183948A1 (en) * | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
| WO2011123785A2 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| EP2911691B1 (de) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| HRP20251395T1 (hr) | 2015-06-04 | 2026-02-13 | Sol-Gel Technologies Ltd. | Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba |
| AU2018205253B2 (en) | 2017-01-06 | 2022-01-13 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| EP3817743A4 (de) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung |
| WO2020118095A1 (en) | 2018-12-06 | 2020-06-11 | OctoTech, Inc. | Rf receiver architectures with parametric circuits |
| JP2024522808A (ja) * | 2021-06-21 | 2024-06-21 | パルヴェラ セラピューティクス、インク． | ゴーリン症候群を治療するための方法および組成物 |
| CN117940170A (zh) | 2021-09-13 | 2024-04-26 | 辛南·塔斯 | 有效干预人类衰老和衰老疾病及其效果 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH649923A5 (de) * | 1980-10-06 | 1985-06-28 | Glaxo Group Ltd | Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide. |
| US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
| DE69841320D1 (de) | 1997-02-10 | 2010-01-07 | Harvard College | Verfahren zur modulation von hämatopoese und vaskulärem wachstum |
| US6238876B1 (en) | 1997-06-20 | 2001-05-29 | New York University | Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma |
| US20050130922A1 (en) | 1997-06-20 | 2005-06-16 | Altaba Ariel R.I. | Method and compositions for inhibiting tumorigenesis |
| US7741298B2 (en) | 1997-06-20 | 2010-06-22 | New York University | Method and compositions for inhibiting tumorigenesis |
| US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| US6867216B1 (en) * | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
| US6432970B2 (en) * | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| CA2326654C (en) * | 1998-04-09 | 2010-11-09 | Johns Hopkins University School Of Medicine | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| ES2233383T3 (es) * | 1999-06-08 | 2005-06-16 | Lorantis Limited | Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog. |
| US20050080138A1 (en) | 1999-09-16 | 2005-04-14 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CA2386190C (en) * | 1999-10-13 | 2009-04-14 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
| US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| AU1935801A (en) * | 1999-11-30 | 2001-06-12 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| US6951839B1 (en) * | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| US6683108B1 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Agonists of hedgehog signaling pathways and uses related thereto |
| US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| AU7549501A (en) | 2000-06-16 | 2002-01-02 | Biogen Inc | Angiogenesis-modulating compositions and uses |
| US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| CU23175A1 (es) * | 2000-07-17 | 2006-09-22 | Ct De Investigacion Y Desarrol | Formulacion liposomica de propionato de clobetasol |
| US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| AU9684401A (en) | 2000-10-13 | 2002-04-22 | Curis Inc | Hedgehog antagonists, methods and uses related thereto |
| US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| JP2004534743A (ja) | 2001-04-09 | 2004-11-18 | ロランティス リミテッド | ヘッジホッグ |
| EP1411938B1 (de) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis |
| EP2862570A1 (de) * | 2001-07-02 | 2015-04-22 | Sinan Tas | Verwendung von Cyclopamin bei der Behandlung eines Basalzellkarzinoms und anderen Tumoren |
| MXPA04003266A (es) * | 2001-10-05 | 2004-07-08 | Combinatorx Inc | Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios. |
| US6927205B2 (en) * | 2003-04-28 | 2005-08-09 | Procyte Corporation | Compositions and methods for treatment of psoriasis |
| KR20050037103A (ko) | 2003-10-17 | 2005-04-21 | 주식회사 엘지생활건강 | 피부 미백용 화장료 조성물 |
| ES2578728T3 (es) * | 2004-08-27 | 2016-07-29 | Infinity Pharmaceuticals, Inc. | Proceso para la preparación de compuestos análogos de ciclopamina |
| US8653083B2 (en) * | 2005-08-22 | 2014-02-18 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
-
2002
- 2002-04-19 EP EP02736467A patent/EP1411938B1/de not_active Expired - Lifetime
- 2002-04-19 CA CA002452152A patent/CA2452152A1/en not_active Abandoned
-
2003
- 2003-03-17 KR KR1020087024138A patent/KR20080096605A/ko not_active Ceased
- 2003-03-17 CN CNA038087847A patent/CN1835748A/zh active Pending
- 2003-03-17 AU AU2003230541A patent/AU2003230541B2/en not_active Ceased
- 2003-03-17 KR KR1020077025034A patent/KR20070108287A/ko not_active Ceased
- 2003-03-17 WO PCT/TR2003/000017 patent/WO2003088964A1/en not_active Ceased
- 2003-03-17 ES ES03723620T patent/ES2253672T3/es not_active Expired - Lifetime
- 2003-03-17 JP JP2003585716A patent/JP2006512281A/ja active Pending
- 2003-03-17 CA CA2481499A patent/CA2481499C/en not_active Expired - Fee Related
- 2003-03-17 CA CA2636960A patent/CA2636960C/en not_active Expired - Fee Related
- 2003-03-17 DE DE60302348T patent/DE60302348T2/de not_active Expired - Lifetime
- 2003-03-17 CN CN200910146214A patent/CN101642458A/zh active Pending
- 2003-03-17 DK DK03723620T patent/DK1496895T3/da active
- 2003-03-17 EA EA200401355A patent/EA200401355A1/ru unknown
- 2003-03-17 KR KR10-2004-7016679A patent/KR20040102117A/ko not_active Ceased
- 2003-03-17 AT AT03723620T patent/ATE309802T1/de not_active IP Right Cessation
- 2003-03-17 MX MXPA04010294A patent/MXPA04010294A/es active IP Right Grant
- 2003-03-17 BR BR0309396-4A patent/BR0309396A/pt not_active IP Right Cessation
- 2003-03-17 KR KR1020087024137A patent/KR20080094739A/ko not_active Ceased
- 2003-03-17 EP EP03723620A patent/EP1496895B1/de not_active Expired - Lifetime
- 2003-10-09 US US10/682,584 patent/US7893078B2/en not_active Expired - Fee Related
- 2003-10-09 US US10/682,662 patent/US7605167B2/en not_active Expired - Fee Related
-
2007
- 2007-10-18 US US11/874,631 patent/US8025893B2/en not_active Expired - Fee Related
- 2007-10-18 US US11/874,653 patent/US7629352B2/en not_active Expired - Fee Related
-
2009
- 2009-07-22 US US12/460,620 patent/US9757361B2/en not_active Expired - Fee Related
-
2011
- 2011-01-13 US US12/930,677 patent/US20110104254A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60302348D1 (de) | Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen | |
| CY1121447T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| CR8380A (es) | Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos | |
| SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| ATE347366T1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
| IL172705A0 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases | |
| WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
| UA84665C2 (ru) | Способ ингибирования опосредствованного ангиогенеза в ткани у пациента с неоваскулярным заболеванием роговицы | |
| ES2166783T3 (es) | Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii. | |
| WO2005030083A3 (en) | Methods and products which utilize n-acyl-l-aspartic acid | |
| DE60042137D1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
| BR0209922A (pt) | Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero | |
| Joseph et al. | Unilateral remission of psoriasis following traumatic nerve palsy | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
| MY134562A (en) | Methods and compositions to treat conditions associated with neovascularization | |
| DE60330888D1 (de) | Verwendung von drospirenon zur behandlung von hypertension | |
| DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
| ATE230609T1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| DE69825279D1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| TW200501934A (en) | Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
| SI1596879T1 (sl) | Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1496895 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |